Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-65 |
Sentence |
denotes |
Oral budesonide in the treatment of chronic refractory pouchitis. |
T2 |
66-77 |
Sentence |
denotes |
BACKGROUND: |
T3 |
78-181 |
Sentence |
denotes |
Pouchitis is the major long-term complication after ileal-pouch nal anastomosis for ulcerative colitis. |
T4 |
182-286 |
Sentence |
denotes |
Ten to 15% of patients develop a chronic pouchitis, either treatment responsive or treatment refractory. |
T5 |
287-291 |
Sentence |
denotes |
AIM: |
T6 |
292-434 |
Sentence |
denotes |
To evaluate the efficacy of oral budesonide in inducing remission and improving quality of life in patients with chronic refractory pouchitis. |
T7 |
435-443 |
Sentence |
denotes |
METHODS: |
T8 |
444-623 |
Sentence |
denotes |
Twenty consecutive patients with active pouchitis, not responding after 1 month of antibiotic treatment were treated with budesonide controlled ileal release 9 mg/day for 8 weeks. |
T9 |
624-766 |
Sentence |
denotes |
Symptomatic, endoscopic and histological evaluations were undertaken before and after treatment according to Pouchitis Disease Activity Index. |
T10 |
767-960 |
Sentence |
denotes |
Remission was defined as a combination of Pouchitis Disease Activity Index clinical score of < or = 2, endoscopic score of < or = 1 and total Pouchitis Disease Activity Index score of < or = 4. |
T11 |
961-1044 |
Sentence |
denotes |
The quality of life was assessed with the Inflammatory Bowel Disease Questionnaire. |
T12 |
1045-1053 |
Sentence |
denotes |
RESULTS: |
T13 |
1054-1102 |
Sentence |
denotes |
Fifteen of 20 patients (75%) achieved remission. |
T14 |
1103-1252 |
Sentence |
denotes |
The median total Pouchitis Disease Activity Index scores before and after therapy were, respectively, 14 (range 9-16) and 3 (range 2-10) (P < 0.001). |
T15 |
1253-1397 |
Sentence |
denotes |
The median Inflammatory Bowel Disease Questionnaire score also significantly improved from 105 (range 77-175) to 180 (range 85-220) (P < 0.001). |
T16 |
1398-1409 |
Sentence |
denotes |
CONCLUSION: |
T17 |
1410-1586 |
Sentence |
denotes |
Eight-week treatment with oral budesonide appears effective in inducing remission in patients with active pouchitis refractory to antibiotic treatment in this open-label study. |
T1 |
0-65 |
Sentence |
denotes |
Oral budesonide in the treatment of chronic refractory pouchitis. |
T2 |
66-77 |
Sentence |
denotes |
BACKGROUND: |
T3 |
78-181 |
Sentence |
denotes |
Pouchitis is the major long-term complication after ileal-pouch nal anastomosis for ulcerative colitis. |
T4 |
182-286 |
Sentence |
denotes |
Ten to 15% of patients develop a chronic pouchitis, either treatment responsive or treatment refractory. |
T5 |
287-291 |
Sentence |
denotes |
AIM: |
T6 |
292-434 |
Sentence |
denotes |
To evaluate the efficacy of oral budesonide in inducing remission and improving quality of life in patients with chronic refractory pouchitis. |
T7 |
435-443 |
Sentence |
denotes |
METHODS: |
T8 |
444-623 |
Sentence |
denotes |
Twenty consecutive patients with active pouchitis, not responding after 1 month of antibiotic treatment were treated with budesonide controlled ileal release 9 mg/day for 8 weeks. |
T9 |
624-766 |
Sentence |
denotes |
Symptomatic, endoscopic and histological evaluations were undertaken before and after treatment according to Pouchitis Disease Activity Index. |
T10 |
767-960 |
Sentence |
denotes |
Remission was defined as a combination of Pouchitis Disease Activity Index clinical score of < or = 2, endoscopic score of < or = 1 and total Pouchitis Disease Activity Index score of < or = 4. |
T11 |
961-1044 |
Sentence |
denotes |
The quality of life was assessed with the Inflammatory Bowel Disease Questionnaire. |
T12 |
1045-1053 |
Sentence |
denotes |
RESULTS: |
T13 |
1054-1102 |
Sentence |
denotes |
Fifteen of 20 patients (75%) achieved remission. |
T14 |
1103-1252 |
Sentence |
denotes |
The median total Pouchitis Disease Activity Index scores before and after therapy were, respectively, 14 (range 9-16) and 3 (range 2-10) (P < 0.001). |
T15 |
1253-1397 |
Sentence |
denotes |
The median Inflammatory Bowel Disease Questionnaire score also significantly improved from 105 (range 77-175) to 180 (range 85-220) (P < 0.001). |
T16 |
1398-1409 |
Sentence |
denotes |
CONCLUSION: |
T17 |
1410-1586 |
Sentence |
denotes |
Eight-week treatment with oral budesonide appears effective in inducing remission in patients with active pouchitis refractory to antibiotic treatment in this open-label study. |